ID: ALA331916

Max Phase: Preclinical

Molecular Formula: C20H19NO3

Molecular Weight: 321.38

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(O)CCCCc1nc(-c2ccccc2)c(-c2ccccc2)o1

Standard InChI:  InChI=1S/C20H19NO3/c22-18(23)14-8-7-13-17-21-19(15-9-3-1-4-10-15)20(24-17)16-11-5-2-6-12-16/h1-6,9-12H,7-8,13-14H2,(H,22,23)

Standard InChI Key:  PREDFJJTVISLLW-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 321.38

Molecular Weight (Monoisotopic): 321.1365

AlogP: 4.81

#Rotatable Bonds: 7

Polar Surface Area: 63.33

Molecular Species: ACID

HBA: 3

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 4.79

CX Basic pKa: 0.40

CX LogP: 4.35

CX LogD: 1.79

Aromatic Rings: 3

Heavy Atoms: 24

QED Weighted: 0.63

Np Likeness Score: -0.20

References

1. Meanwell NA, Rosenfeld MJ, Trehan AK, Wright JJ, Brassard CL, Buchanan JO, Federici ME, Fleming JS, Gamberdella M, Zavoico GB..  (1992)  Nonprostanoid prostacyclin mimetics. 2. 4,5-Diphenyloxazole derivatives.,  35  (19): [PMID:1404230] [10.1021/jm00097a006]

2. Schierle S, Chaikuad A, Lillich FF, Ni X, Woltersdorf S, Schallmayer E, Renelt B, Ronchetti R, Knapp S, Proschak E, Merk D..  (2021)  Oxaprozin Analogues as Selective RXR Agonists with Superior Properties and Pharmacokinetics.,  64  (8.0): [PMID:33793232] [10.1021/acs.jmedchem.1c00235]

Source

Source(1):

• Scientific Literature